2022-2023季节性流感疫苗在美国65岁及以上成人中潜在不良事件的评估
本研究采用自我对照病例系列方法,分析2022-2023季节性流感疫苗接种后65岁及以上美国Medicare受益人中过敏反应、脑炎/脑脊髓炎、吉兰-巴雷综合征(GBS)和横贯性脊髓炎的发生率。过敏反应升高可能受同期接种影响。
要点
- 2022-2023流感疫苗接种后,脑炎/脑脊髓炎、GBS和横贯性脊髓炎发生率未升高。
- 过敏反应发生率在风险期较对照期升高但未达统计学显著(任何疫苗IRR 2.40,95%CI 0.96-6.03)。
- 过敏反应升高可能受同期接种其他疫苗影响。
核心结论
- 2022-2023季节性流感疫苗接种后,美国65岁及以上成人中脑炎/脑脊髓炎、吉兰-巴雷综合征和横贯性脊髓炎的发生率未升高。
- 疫苗接种后过敏反应发生率升高,但未达统计学显著,且可能受同期接种影响。
研究设计与样本
- 采用自我对照病例系列设计,比较2022-2023季节性流感疫苗接种后风险期与对照期的发生率。
- 使用条件Poisson回归估计发病率比(IRR)和95%置信区间(CI),并调整事件依赖观察时间和季节性。
- 在可行时考虑结局错分的不确定性。
- 对任何有统计学显著关联的不良事件,按同期接种状态进行分层分析。
主要发现
- 共观察到76例过敏反应、276例脑炎/脑脊髓炎、134例吉兰-巴雷综合征和75例横贯性脊髓炎。
- 仅过敏反应在风险期较对照期升高。
- 经所有调整后,任何流感疫苗接种后过敏反应IRR为2.40(95%CI 0.96-6.03),未达统计学显著。
- 高剂量疫苗过敏反应IRR为2.31(95%CI 0.67-7.91),佐剂疫苗过敏反应IRR为3.28(95%CI 0.71-15.08),均未达统计学显著。
- 有同期接种者过敏反应IRR为2.54(95%CI 0.49-13.05),无同期接种者IRR为1.64(95%CI 0.38-7.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While safety of influenza vaccines is well-established, some studies have suggested potential associations between influenza vaccines and certain adverse events (AEs). This study examined the safety of the 2022-2023 influenza vaccines among U.S. adults ≥ 65 years. METHODS: A self-controlled case series compared incidence rates of anaphylaxis, encephalitis/encephalomyelitis, Guillain-Barré Syndrome (GBS), and transverse myelitis following 2022-2023 seasonal influenza vaccinations (i.e., any, high-dose or adjuvanted) in risk and control intervals among Medicare beneficiaries ≥ 65 years. We used conditional Poisson regression to estimate incidence rate ratios (IRRs) and 95 % confidence intervals (CIs) adjusted for event-dependent observation time and seasonality. Analyses also accounted for uncertainty from outcome misclassification where feasible. For AEs with any statistically significant associations, we stratified results by concomitant vaccination status. RESULTS: Among 12.7 million vaccine recipients, we observed 76 anaphylaxis, 276 encephalitis/encephalomyelitis, 134 GBS and 75 transverse myelitis cases. Only rates of anaphylaxis were elevated in risk compared to control intervals. With all adjustments, an elevated, but non-statistically significant, anaphylaxis rate was observed following any (IRR: 2.40, 95% CI: 0.96-6.03), high-dose (IRR: 2.31, 95% CI: 0.67-7.91), and adjuvanted (IRR: 3.28, 95% CI: 0.71-15.08) influenza vaccination; anaphylaxis IRRs were 2.54 (95% CI: 0.49-13.05) and 1.64 (95% CI: 0.38-7.05) for persons with and without concomitant vaccination, respectively. CONCLUSIONS: Rates of encephalitis/encephalomyelitis, GBS, or transverse myelitis were not elevated following 2022-2023 seasonal influenza vaccinations among U.S. adults ≥ 65 years. There was an increased rate of anaphylaxis following influenza vaccination that may have been influenced by concomitant vaccination.
引用
- Shi XC, Gruber JF, Ondari M, et al. Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older. Vaccine. 2024. PMID: 38704258. doi:10.1016/j.vaccine.2024.04.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。